We therefore suggest that concurrent inhibition of CHK1 and BRD4, as prioritized by SSO‐QPOP, is a promising treatment approach for MYC‐driven HCC, and that ssCHK1 and ssBRD4 can serve as promising candidate therapeutic agents following subsequent optimization. This evidence concerns the gene MYC and hepatocellular carcinoma.